Bevacizumab Market: By Application (Colorectal Cancer, Lung Cancer, Breast Cancer, Renal Cancer, Brain Cancer, Eye Diseases, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography  

Bevacizumab Market size is valued at USD 8.50 billion in 2022 and is poised to grow at a CAGR of 9.2% during the forecast period 2023-2029. Bevacizumab, often known as Avastin, is a prescription drug used to treat a variety of tumours and specific eye problems. It is used for colon illness, cellular breakdown in the lungs, glioblastoma, and renal cell carcinoma and is given as a slow infusion into a vein (intravenous). Bevacizumab is used as a first-line treatment for several of these disorders. It is infused into the eye to treat age-related macular degeneration (intravitreal). When used to treat disease, bevacizumab has certain common side effects, including nosebleeds, migraines, hypertension, and dermatitis. Other serious side effects include gastrointestinal bleeding, mortality, negatively susceptible responses, blood clusters, and an increased risk of contamination. When used to treat eye disease, side effects can include vision problems and retinal separation. Bevacizumab is a monoclonal neutralizer with anti-angiogenesis properties. It acts by slowing the growth of new blood vessels by inhibiting vascular endothelial development factor A (VEGF-A), a major VEGF antagonist. this report studies global Market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global Bevacizumab Market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global Bevacizumab Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).